News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Pulmovant (Roivant) will present topline Phase 2 PHocus results for mosliciguat in PH-ILD at the ERS Congress on Sept 8.
  • Roivant will host an investor call immediately after the ERS presentation to discuss the topline findings.
  • Topline results will affect Pulmovant and respiratory-biotech sector valuations.
  • Star Group offers a yield above 6% and has raised distributions for 14 consecutive years.
  • Star Group generates roughly $56.8M in free cash flow with an enterprise value below $600M.
  • SGU trades at about a 5.2 P/E and ~3.2 EV/EBITDA, framing it as a reversion/value trade for income investors.

Latest Articles

Baidu: Kunlunxin IPO Is the Catalyst That Could Re-Price the AI Story

Baidu: Kunlunxin IPO Is the Catalyst That Could Re-Price the AI Story

Baidu trades at $92.37 with a $37.3B market cap and oversold momentum. The planned IPO of Kunlunxin - Baidu's AI chip and model arm - could force the market to separately value Baidu's high-growth AI franchise versus its legacy search and iQiyi segments. This trade targets a mid-term re-rating on positive IPO reception, product wins, or acceleratin…

Why Marvell’s Rally Looks Pricy: A Short Trade to Fade the Hype

Why Marvell’s Rally Looks Pricy: A Short Trade to Fade the Hype

Marvell has been swept up in AI infrastructure enthusiasm. The stock is richly valued on thin margin of error: market cap near $205B, trailing P/E in the 70s and FCF yield below 1%. This trade idea proposes a tactical short to fade an overstretched move while offering clear entry, stop and target levels with a mid-term horizon.

Nu Holdings: Still Early in Latin America’s Digital Banking Story

Nu Holdings: Still Early in Latin America’s Digital Banking Story

Nu Holdings remains one of the highest-conviction growth stories in Latin American fintech. Recent results show 50% revenue growth, a profitable earnings inflection and accelerating monetization per user. With Mexico now open and strong early traction in Colombia, the stock looks well positioned for further multiple expansion. This trade idea lays …

Array Technologies: Q2 Check — Buy to Ride a 2027 Product Inflection

Array Technologies: Q2 Check — Buy to Ride a 2027 Product Inflection

Array Technologies is at an inflection: a new 60-degree DuraTrack variant and solid free cash flow position give the company room to win larger, weather-hardened utility projects in 2027. At a sub-$800M market cap and FCF of $134.7M, the risk/reward looks favorable for a long trade into mid-2027, provided developers lean into hail-resistant tracker…

Choosing Between WTI and Brent: A Practical Guide for New Oil Traders

Choosing Between WTI and Brent: A Practical Guide for New Oil Traders

WTI (West Texas Intermediate) and Brent are the two dominant crude benchmarks, trading at $85.10 and $92.23 respectively, leaving a $7.13 spread that reflects geography, supply risk and market structure. For newcomers, WTI typically offers clearer news linkage, deeper liquidity and lower apparent geopolitical sensitivity; Brent is the more global g…

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Regeneron Pharmaceuticals announced FDA approval of Pasatru™ (garetosmab-grts) for adults with FOP, a rare genetic disorder causing abnormal bone growth. In the positive Phase 3 OPTIMA trial, Pasatru significantly reduced new heterotopic ossification lesions by over 90% and decreased clinician-assessed flare-ups compared to placebo, providing a tra…

Moderna's Rally: Short Squeeze Meets Real Clinical Breakthrough

Moderna's Rally: Short Squeeze Meets Real Clinical Breakthrough

Moderna shares vaulted 142.74% to $152.83 intraday after a Phase 3 readout for its personalized mRNA cancer vaccine, triggering a large short squeeze against 13.5% short interest. While the clinical result marks a first for mRNA oncology and underpins a substantive re-rating, technical indicators and valuation gaps raise significant mean-reversion …

Tesla Is Quietly Regrading Its Risk/Reward — A Mid-Run Long Setup

Tesla Is Quietly Regrading Its Risk/Reward — A Mid-Run Long Setup

Tesla shares are down materially from last year's highs, but several underappreciated operational developments and compressed expectations create a defined-risk entry. This trade targets a rebound into the low $400s over the next 45 trading days, with a stop below key technical support and clear exit criteria if robotaxi delays or margin deteriorat…

CZMWY Eyeing a Rebound: Tactical Long After Technical Confirmation

CZMWY Eyeing a Rebound: Tactical Long After Technical Confirmation

Carl Zeiss Meditec (CZMWY) has bounced off its March low and technicals now show sustained bullish momentum. With a $3.36B market cap, improving moving averages, and tailwinds in ophthalmics and advanced optics, this trade aims to capture a re-acceleration over the next 45 trading days. Entry, stop and target are defined with a clearly articulated …

Chemung Financial Corporation Announces Dividend Increase

Chemung Financial Corporation Announces Dividend Increase

Chemung Financial Corporation announced a 5.9% increase in its quarterly dividend to $0.36 per share, marking a total dividend rise of 16.1% since 2025. This move demonstrates the company’s robust financial position and ongoing commitment to returning value to shareholders. The dividend will be payable on October 1, 2026, to shareholders of record …

Lyntris Shares Slide 11% After Downsized IPO; Company Raises $297.5 Million

Lyntris Shares Slide 11% After Downsized IPO; Company Raises $297.5 Million

Lyntris Inc. raised $297.5 million in a reduced initial public offering but its shares opened below the offering price, falling about 11% in their first day of trading. The Falls Church, Virginia-based sensor company priced 17 million shares at $17.50 each and opened on the NYSE at $15.50, giving it a market value of $1.68 billion based on outstand…

Canada and U.S. Trade Teams Hold Talks After Trump Pauses New Tariffs

Canada and U.S. Trade Teams Hold Talks After Trump Pauses New Tariffs

Canadian and U.S. trade officials met in Ottawa after U.S. President Donald Trump temporarily paused planned 50% tariffs on some Canadian products for three days. Negotiators are working against a new deadline of 12:01 a.m. ET on Saturday when tariffs on $20 billion of Canadian goods would take effect if no agreement is reached. Auto tariffs, rules…